Omega Therapeutics Revenue and Competitors

Boston, MA USA

Location

$239.4M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Omega Therapeutics's estimated annual revenue is currently $16.3M per year.(i)
  • Omega Therapeutics's estimated revenue per employee is $117,935
  • Omega Therapeutics's total funding is $239.4M.
  • Omega Therapeutics's current valuation is $509.3M. (January 2022)

Employee Data

  • Omega Therapeutics has 138 Employees.(i)
  • Omega Therapeutics grew their employee count by 6% last year.

Omega Therapeutics's People

NameTitleEmail/Phone
1
Executive Director Business DevelopmentReveal Email/Phone
2
CEOReveal Email/Phone
3
Chief StaffReveal Email/Phone
4
SVP, FinanceReveal Email/Phone
5
SVP, Head Regulatory AffairsReveal Email/Phone
6
VP, Intellectual Property (IP)Reveal Email/Phone
7
VP, Data and ITReveal Email/Phone
8
Associate DirectorReveal Email/Phone
9
Senior Director, Cancer Biology (through Nov 2023)Reveal Email/Phone
10
Executive Director, FinanceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Omega Therapeutics?

Omega Therapeuticsᅢᄁ¬ダᅡᄁ is a preclinical stage genomic medicine enterprise transforming medicine and patient care through precision genomic control. The companyᅢᄁ¬ツᆲ¬トᄁs platform is focused on selectively directing the human genome to treat and cure disease by precisely controlling genomic expression without changing nucleic acid sequences. We are developing precision therapeutics for a range of disease indications including rare genetic diseases, immunology, inflammation, metabolic diseases and oncology. # transformativemedicines #pioneeringmedicines

keywords:N/A

$239.4M

Total Funding

138

Number of Employees

$16.3M

Revenue (est)

6%

Employee Growth %

$509.3M

Valuation

N/A

Accelerator

Omega Therapeutics News

2022-04-17 - Short Interest in Omega Therapeutics, Inc. (NASDAQ:OMGA ...

Get Omega Therapeutics alerts: Hedge funds and other institutional investors have recently added to or reduced their stakes in the business.

2022-04-06 - Omega Therapeutics Presents Preclinical Data on OTX-2002 ...

Omega Therapeutics Presents Preclinical Data on OTX-2002, First-in-Class Epigenomic Controller, as Potential Treatment for Hepatocellular...

2022-03-30 - Omega Therapeutics Strengthens Team With Key ...

(Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new...

2021-09-10 - Omega Therapeutics Reports Second Quarter 2021 Financial Results and Outlines Key Corporate Objectives

CAMBRIDGE, Mass., Sept. 10, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ pl ...

2021-07-29 - Omega Therapeutics Announces Pricing of Initial Public Offering

CAMBRIDGE, Mass, July 29, 2021 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming™ platform to harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded p ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$35.1M13810%N/A
#2
$37.5M1391%N/A
#3
$34.1M13924%N/A
#4
$28.4M13951%N/A
#5
N/A13972%N/A